Health · World
AstraZeneca drug shows benefits in lung disease trials
AstraZeneca's drug for chronic obstructive pulmonary disease (COPD) has demonstrated benefits across different patient groups in late-stage trials. Full data from these trials are expected to bolster the drug's potential as a blockbuster medication. The trials focused on the drug's efficacy and positive outcomes for patients suffering from lung disease.
How outlets across the spectrum covered it
L 0 C 2 R 0
- Centre (2): CNBC, The Wall Street Journal